Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-06-02 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings
2011-06-02 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations release highlighting clinical trial data and research updates presented at the American Society of Clinical Oncology (ASCO) meeting. It includes detailed descriptions of clinical studies, drug information, and safety information but does not contain comprehensive financial statements or detailed financial performance data. The document is not an earnings release, annual or interim report, audit report, or management discussion. It is a regulatory filing used to disclose material information to the SEC about ongoing clinical developments and corporate updates. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but a substantive disclosure, fitting the RNS category rather than a report publication announcement or other categories.
2011-06-01 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, submitted to the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The content is an investor relations release announcing positive results from two Phase III clinical trials of ACZ885 for severe gouty arthritis, including study details, efficacy data, and regulatory filing updates. It is a detailed announcement of clinical trial results and regulatory progress rather than a full financial report, earnings release, or management discussion. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or any other financial report type. It is also not a proxy, voting result, or governance document. The document is a regulatory announcement of clinical trial results and regulatory filings, typical of a Regulatory Filing (RNS) category. The length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2011-05-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing a US patent infringement lawsuit victory related to Alcon's Patanol product. There are no financial statements, detailed financial performance data, or comprehensive management discussion of results. The document is a regulatory announcement providing material information to investors but does not constitute an annual or interim report, earnings release, or other detailed financial report. It is not a certification or attestation document either. Given the nature of the filing (Form 6-K) and the content (press release about legal and patent matters), the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2011-05-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release about the endorsement of the Pandemic Influenza Preparedness Framework at the World Health Assembly. It discusses Novartis's commitment to pandemic preparedness and vaccine production but does not contain financial statements or detailed financial analysis. The document length is 9320 characters, which is relatively short and primarily contains a press release rather than a comprehensive financial report. There is no indication that this is an annual report, interim report, earnings release, or any other detailed financial filing. It is a regulatory filing providing information to investors and the SEC but does not fit into more specific categories like earnings release or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-05-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes restated and pro forma consolidated income statement data following a merger with Alcon, but it does not contain full audited financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It also announces an investor call to discuss the data and provides a press release summary. The document is about providing updated financial data and an announcement rather than the full report itself. Given the length (9674 characters) and the nature of the content, it is a regulatory announcement of financial data updates and restatements rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2011-05-19 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.